Long noncoding RNAs mediate endocrine signaling and resistance in prostate cancer
Endocrinology · 08.07.2026 · 167 (8)
DOI: 10.1210/endocr/bqag076 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Endocrinology, online erschienen am 02.07.2026. Verfasst von Daniel Gioeli. Beteiligte Einrichtung: Department of Urology, University of Virginia, and University of Virginia NCI-Designated Comprehensive Cancer Center, Charlottesville, VA 22908, USA. Hauptthemen laut MEDLINE: RNA, Long Noncoding, Drug Resistance, Neoplasm, Prostatic Neoplasms, Prostatic Neoplasms, Castration-Resistant. Die Arbeit nennt 102 Literaturangaben. Gefördert von: NCI NIH HHS, University of Virginia NCI, University of Virginia Department of Urology.
Abstract (Originalsprache)
Prostate cancer (PCa) represents a hormone-dependent malignancy where androgen receptor (AR) signaling plays a central role in disease initiation, progression, and therapeutic resistance. Recent advances have revealed that long noncoding RNAs (lncRNAs) constitute a critical regulatory layer in PCa, with implications for endocrine signaling pathways. lncRNAs orchestrate complex gene regulatory networks through diverse molecular mechanisms including chromatin remodeling, AR splice variant regulation, competitive endogenous RNA networks, translational control, and metabolic reprogramming. In castration-resistant PCa, dysregulated lncRNAs contribute to resistance against androgen deprivation therapy and next-generation AR antagonists such as enzalutamide. This review synthesizes current knowledge on lncRNA biology in PCa, emphasizing lncRNA relationships with AR signaling and endocrine resistance mechanisms. We discuss key lncRNAs that modulate AR activity, metabolic adaptation, and lineage plasticity. Additionally, we examine structure–function relationships that enable rational therapeutic design, lncRNA roles in bone metastasis and neuroendocrine differentiation, and lncRNA clinical utility as biomarkers for disease progression and treatment stratification. Therapeutic strategies include antisense oligonucleotides, small-molecule inhibitors of lncRNA–protein interaction disruptors, and combination approaches with DNA-damaging agents and AR inhibitors. Understanding lncRNA-mediated endocrine regulation provides insights into PCa biology and offers avenues for overcoming therapeutic resistance in advanced disease.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Urology, University of Virginia, and University of Virginia NCI-Designated Comprehensive Cancer Center, Charlottesville, VA 22908, USA.
ORCID-Profile: Daniel Gioeli
Förderung
- NCI NIH HHS
- University of Virginia NCI
- University of Virginia Department of Urology
- NCI
Zitieren
APA
Gioeli, D. (2026). Long noncoding RNAs mediate endocrine signaling and resistance in prostate cancer. Endocrinology, 167(8). https://doi.org/10.1210/endocr/bqag076
Vancouver
Gioeli D. Long noncoding RNAs mediate endocrine signaling and resistance in prostate cancer. Endocrinology. 2026;167(8). doi:10.1210/endocr/bqag076
BibTeX
@article{Gioeli2026,
author = {Gioeli, Daniel},
title = {Long noncoding RNAs mediate endocrine signaling and resistance in prostate cancer},
journal = {Endocrinology},
year = {2026},
volume = {167},
number = {8},
doi = {10.1210/endocr/bqag076}
}
EUVIMED